Carlos Costa - 20 Sep 2024 Form 4 Insider Report for Foghorn Therapeutics Inc. (FHTX)

Role
Chief People Officer
Signature
/s/ Michael LaCascia, Attorney-in-Fact for Carlos Costa
Issuer symbol
FHTX
Transactions as of
20 Sep 2024
Net transactions value
-$231,506
Form type
4
Filing time
24 Sep 2024, 16:01:55 UTC
Previous filing
20 Sep 2024
Next filing
24 Jan 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction FHTX Common Stock Options Exercise $133,012 +35,756 $3.72 35,756 20 Sep 2024 Direct F1
transaction FHTX Common Stock Sale $358,990 -35,756 -100% $10.04 0 20 Sep 2024 Direct F1, F2
transaction FHTX Common Stock Options Exercise $3,188 +857 $3.72 857 23 Sep 2024 Direct F1
transaction FHTX Common Stock Sale $8,716 -857 -100% $10.17 0 23 Sep 2024 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction FHTX Stock Option (right to buy) Options Exercise $0 -35,756 -47% $0.000000 40,646 20 Sep 2024 Common Stock 35,756 $3.72 Direct F1, F3
transaction FHTX Stock Option (right to buy) Options Exercise $0 -857 -2.1% $0.000000 39,789 23 Sep 2024 Common Stock 857 $3.72 Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan that was adopted by the reporting person on March 11, 2024.
F2 The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $10.00 to $10.22 per share.
F3 The option vested as to 25% of the underlying shares of common stock on August 29, 2019, and at a rate of 6.25% of the underlying shares thereafter on the first day of each calendar quarter following such first anniversary until the option was fully vested.